Novartis Expands Antibiotic Capacity in Slovenia

Novartis’ generic arm Sandoz has confirmed the expansion of the production of broad-spectrum antibiotic at the Prevalje Penicillin Site, the company announced in a Jan. 27, 2017 press release. The investment will significantly increase the existing capacity and will be ongoing over several years. If the investment proceeds as planned, the first production lines will start in 2019, after which new lines will be gradually phased in by 2023.

Novartis, one of the biggest investors in Slovenia, invested more than 30 million Euros in development and modernization of facilities in Prevalje over the last ten years. ''Our products are used for treating patients in 60 markets. In recent years, the demand has been continuously growing and in order to meet this demand, we have recently introduced a number of process improvements. We are pleased that Novartis has decided to invest, as the expansion of the current capacity will facilitate further development of the site and employment,'' said Zlatko Ajd, head of Penicillin Products Production Prevalje, in the press release. 

Source: Lek